Obstructive sleep apnea and cardiovascular disease - A new target for treatment

Current Pharmaceutical Design

Volumn 21, Issue 24, 2015, Pages 3496-3504

  Schillaci, Giuseppe ^a,b   Battista, Francesca ^a,b   Fiorenzano, Giuseppe ^b   Basili, Maria Cristina ^b   Crapa, Mariano ^a,b   Alrashdi, Yahya ^a   Pucci, Giacomo ^a,b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Azienda Ospedaliero Universitaria di Terni   (Italy)

Author keywords

Cardiovascular diseases; Coronary heart disease; Endothelial dysfunction; Heart failure; Hypertension; Obstructive sleep apnea; Stroke

Indexed keywords

ADRENERGIC SYSTEM; AROUSAL; ARTERIAL STIFFNESS; ARTICLE; ATELECTASIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; INFLAMMATION; INTERMITTENT HYPOXIA; META ANALYSIS (TOPIC); NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHARYNX; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REOXYGENATION; RESISTANT HYPERTENSION; SLEEP DISORDERED BREATHING; SLEEP TIME; THORAX PRESSURE; ANIMAL; CARDIOVASCULAR DISEASES; COMPLICATION; PHYSIOLOGY; PROCEDURES; RISK FACTOR; SLEEP; SLEEP APNEA, OBSTRUCTIVE;

ANIMALS; CARDIOVASCULAR DISEASES; CONTINUOUS POSITIVE AIRWAY PRESSURE; HUMANS; HYPERTENSION; PATIENT COMPLIANCE; RISK FACTORS; SLEEP; SLEEP APNEA, OBSTRUCTIVE;

EID: 84939833386     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150706110544     Document Type: Article

References (131)

1. Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/american College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation 2008; 118: 1080-111.
2. Sánchez-de-la-Torre M, Campos-Rodriguez F, Barbé F. Obstructive sleep apnoea and cardiovascular disease. Lancet Respir Med 2013; 1: 61-72.
3. Kump K, Whalen C, Tishler PV, et al. Assessment of the validity and utility of a sleep-symptom questionnaire. Am J Respir Crit Care Med 1994; 150: 735-41.
4. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540-5.
5. Epstein LJ, Kristo D, Strollo PJ Jr., et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med 2009; 5: 263-76.
6. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993; 328: 1230-5.
7. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 2013; 177: 1006-14.
8. Hägg SA, Torén K, Lindberg E. Role of sleep disturbances in occupational accidents among women. Scand J Work Environ Health 2015; 41(4): 368-76.
9. Arita A, Sasanabe R, Hasegawa R, et al. Risk factors for automobile accidents caused by falling asleep while driving in obstructive sleep apnea syndrome. Sleep Breath 2015; [Epub ahead of print].
10. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365: 1046-53.
11. Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep 2008; 31: 1071-8.
12. Marshall NS, Wong KK, Liu PY, Cullen SR, Knuiman MW, Grunstein RR. Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study. Sleep 2008; 31: 1079-85.
13. Punjabi NM, Caffo BS, Goodwin JL, et al. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med 2009; 6: e1000132.
14. Redline S, Yenokyan G, Gottlieb DJ, et al. Obstructive sleep apneahypopnea and incident stroke: the Sleep Heart Health Study. Am J Respir Crit Care Med 2010; 182: 269-277.
15. Scherrer U, Randin D, Tappy L, Vollenweider P, Jéquier E, Nicod P. Body fat and sympathetic nerve activity in healthy subjects. Circulation 1994; 89: 2634-40.
16. Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 1995; 96: 1897-904.
17. Somers VK, Mark AL, Zavala DC, Abboud FM. Contrasting effects of hypoxia and hypercapnia on ventilation and sympathetic activity in humans. J Appl Physiol 1989; 67: 2101-6.
18. Fletcher EC, Bao G, Li R. Renin activity and blood pressure in response to chronic episodic hypoxia. Hypertension 1999; 34: 309- 14.
19. Fletcher EC, Lesske J, Qian W, et al. Repetitive, episodic hypoxia causes diurnal elevation of blood pressure in rats. Hypertension 1992; 19: 555-61.
20. Bao G, Metreveli N, Li R, et al. Blood pressure response to chronic episodic hypoxia: Role of the sympathetic nervous system. J Appl Physiol 1997; 83: 95-101.
21. Fletcher EC, Lesske J, Culman J, et al. Sympathetic denervation blocks blood pressure elevation in episodic hypoxia. Hypertension 1992; 20: 612-9.
22. Tamisier R, Pepin JL, Remy J, et al. 14 nights of intermittent hypoxia elevate daytime blood pressure and sympathetic activity in healthy humans. Eur Respir J 2011; 37: 119-28.
23. Fletcher EC, Miller J, Schaaf JW, et al. Urinary catecholamines before and after tracheostomy in patients with obstructive sleep apnea and hypertension. Sleep 1987; 10: 35-44.
24. Dimsdale JE, Coy T, Ziegler MG, et al. The effect of sleep apnea on plasma and urinary catecholamines. Sleep 1995; 18: 377-81.
25. Elmasry A, Lindberg E, Hedner J, et al. Obstructive sleep apnoea and urine catecholamines in hypertensive males: a population-based study. Eur Respir J 2002; 19: 511-7.
26. Hedner J, Darpo B, Ejnell H, et al. Reduction in sympathetic activity after long-term cpap treatment in sleep apnoea: cardiovascular implications. Eur Respir J 1995; 8: 222-9.
27. Ziegler MG, Mills PJ, Loredo JS, et al. Effect of continuous positive airway pressure and placebo treatment on sympathetic nervous activity in patients with obstructive sleep apnea. Chest 2001; 120: 887-93.
28. Carlson JT, Hedner J, Elam M, et al. Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest 1993; 103: 1763-8.
29. Narkiewicz K, Kato M, Phillips BG, et al. Nocturnal continuous positive airway pressure decreases daytime sympathetic traffic in obstructive sleep apnea. Circulation 1999; 100: 2332-5.
30. Carlson JT, Hedner JA, Sellgren J, et al. Depressed baroreflex sensitivity in patients with obstructive sleep apnea. Am J Respir Crit Care Med 1996; 154: 1490-6.
31. Bonsignore MR, Parati G, Insalaco G, et al. Continuous positive airway pressure treatment improves baroreflex control of heart rate during sleep in severe obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2002; 166: 279-86.
32. Ryan S, Ward S, Heneghan C, et al. Predictors of decreased spontaneous baroreflex sensitivity in obstructive sleep apnea syndrome. Chest 2007; 131: 1100-7.
33. Nelesen RA, Yu H, Ziegler MG, Mills PJ, Clausen JL, Dimsdale JE. Continuous positive airway pressure normalizes cardiac autonomic and hemodynamic responses to a laboratory stressor in apneic patients. Chest 2001; 119: 1092-101.
34. Lavie L. Obstructive sleep apnea syndrome-an oxidative stress disorder. Sleep Med Rev 2003; 7: 35-51.
35. Chen L, Einbinder E, Zhang Q, et al. Oxidative stress and left ventricular function with chronic intermittent hypoxia in rats. Am J Respir Crit Care Med 2005; 172: 915-20.
36. Barcelo A, Miralles C, Barbe F, et al. Abnormal lipid peroxidation in patients with sleep apnoea. Eur Respir J 2000; 16: 644-7.
37. Lavie L, Vishnevsky A, Lavie P. Evidence for lipid peroxidation in obstructive sleep apnea. Sleep 2004; 27: 123-8.
38. Alonso-Fernández A, García-Río F, Arias MA, et al. Effects of CPAP on oxidative stress and nitrate efficiency in sleep apnea: a randomised trial. Thorax 2009; 64: 581-6.
39. Jelic S, Padeletti M, Kawut SM, et al. Inflammation, oxidative stress, and repair capacity of the vascular endothelium in obstructive sleep apnea. Circulation 2008; 117: 2270-8.
40. Grebe M, Eisele HJ, Weissmann N, et al. Antioxidant vitamin C improves endothelial function in obstructive sleep apnea. Am J Respir Crit Care Med 2006; 173: 897-901.
41. Myung SK, Ju W, Cho B, et al. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ 2013; 346: f10.
42. Ryan S, Taylor CT, McNicholas WT. Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome? Thorax 2009; 64: 631-6.
43. Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 2005; 112: 2660-7.
44. Harsch IA, Konturek PC, Kebnick C, et al. Leptin and ghrelin levels in patients with obstructive sleep apnea: effect of CPAP treatment. Eur Respir J 2003; 22: 251-7.
45. Larkin EK, Rosen CL, Kirchner HL, et al. Variation of C-reactive protein levels in adolescents: association with sleep-disordered breathing and sleep duration. Circulation 2005; 111: 1978-84.
46. Drager LF, Lopes HF, Maki-Nunes C, et al. The impact of obstructive sleep apnea on metabolic and inflammatory markers in consecutive patients with metabolic syndrome. PLoS One 2010; 5: e12065.
47. Guilleminault C, Kirisoglu C, Ohayon MM. C-reactive protein and sleep-disordered breathing. Sleep 2004; 27: 1507-11.
48. Kohler M, Ayers L, Pepperell JCT, et al. Effects of continuous positive airway pressure on systemic inflammation in patients with moderate to severe obstructive sleep apnoea: a randomised controlled trial. Thorax 2009; 64: 67-73.
49. Sekosan M, Zakkar M, Wenig BL, Olopade CO, Rubinstein I. Inflammation in the uvula mucosa of patients with obstructive sleep apnea. Laryngoscope 1996; 106: 1018-20.
50. Amatoury J, Howitt L, Wheatley JR, Avolio AP, Amis TC. Snoring- related energy transmission to the carotid artery in rabbits. J Appl Physiol 2006; 100: 1547-53.
51. Cho JG, Witting PK, Verma M, et al. Tissue vibration induces carotid artery endothelial dysfunction: a mechanism linking snoring and carotid atherosclerosis? Sleep 2011; 34: 751-7.
52. Lee SA, Amis TC, Byth K, et al. Heavy snoring as a cause of carotid artery atherosclerosis. Sleep 2008; 31: 1207-13.
53. Budhiraja R, Parthasarathy S, Quan SF. Endothelial dysfunction in obstructive sleep apnea. J Clin Sleep Med 2007; 3: 409-15.
54. Hoyos CM, Melehan KL, Liu PY, Grunstein RR, Phillips CL. Does obstructive sleep apnea cause endothelial dysfunction? A critical review of the literature. Sleep Med Rev 2015; 20: 15-26.
55. Bruno RM, Rossi L, Fabbrini M, et al. Renal vasodilating capacity and endothelial function are impaired in patients with obstructive sleep apnea syndrome and no traditional cardiovascular risk factors. J Hypertens 2013; 31: 1456-64.
56. Nieto FJ, Herrington DM, Redline S, Benjamin EJ, Robbins JA. Sleep apnea and markers of vascular endothelial function in a large community sample of older adults. Am J Respir Crit Care Med 2004; 169: 354-60.
57. Vgontzas AN, Papanicolaou DA, Bixler EO, et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000; 85: 1151-8.
58. Hashimoto M, Akishita M, Eto M, et al. The impairment of flowmediated vasodilatation in obese men with visceral fat accumulation. Int J Obes Relat Metab Disord 1998; 22: 477-84.
59. Sturm W, Sandhofer A, Engl J, et al. Influence of visceral obesity and liver fat on vascular structure and function in obese subjects. Obes (Silver Spring) 2009; 17: 1783-8.
60. Romero-Corral A, Sert-Kuniyoshi FH, Sierra-Johnson J, et al. Modest visceral fat gain causes endothelial dysfunction in healthy humans. J Am Coll Cardiol 2010; 56: 662-6.
61. Kohler M, Stoewhas A-C, Ayers L, et al. Effects of continuous positive airway pressure therapy withdrawal in patients with obstructive sleep apnea: a randomized controlled trial. Am J Respir Crit Care Med 2011; 184: 1192-9.
62. Larsson PT, Wallén NH, Hjemdahl P. Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation 1994; 89: 1951-7.
63. Rångemark C, Hedner JA, Carlson JT, Gleerup G, Winther K. Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apnea patients. Sleep 1995; 18: 188-94.
64. von Känel R, Dimsdale JE. Hemostatic alterations in patients with obstructive sleep apnea and the implications for cardiovascular disease. Chest 2003; 124: 1956-67.
65. Phillips CL, McEwen BJ, Morel-Kopp MC, et al. Effects of continuous positive airway pressure on coagulability in obstructive sleep apnoea: a randomised, placebo-controlled crossover study. Thorax 2012; 67: 639-44.
66. Toukh M, Pereira EJ, Falcon BJ, et al. CPAP reduces hypercoagulability, as assessed by thromboelastography, in severe obstructive sleep apnoea. Respir Physiol Neurobiol 2012; 183: 218-23.
67. Phillips CL, Butlin M, Wong KK, Avolio AP. Is obstructive sleep apnoea causally related to arterial stiffness? A critical review of the experimental evidence. Sleep Med Rev 2013; 17: 7-18.
68. Weiss JW, Remsburg S, Garpestad E, Ringler J, Sparrow D, Parker JA. Hemodynamic consequences of obstructive sleep apnea. Sleep 1996; 19: 388-97.
69. Cappuccio FP, Cooper D, D'Elia L, Strazzullo P, Miller MA. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Eur Heart J 2011; 32: 1484- 92.
70. Xiao Q, Keadle SK, Hollenbeck AR, Matthews CE. Sleep duration and total and cause-specific mortality in a large US cohort: interrelationships with physical activity, sedentary behavior, and body mass index. Am J Epidemiol 2014; 180: 997-1006.
71. Bruno RM, Palagini L, Gemignani A, et al. Poor sleep quality and resistant hypertension. Sleep Med 2013; 14: 1157-63.
72. Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet 1999; 354: 1435-9.
73. Patel SR, Zhu X, Storfer-Isser A, et al. Sleep duration and biomarkers of inflammation. Sleep 2009; 32: 200-4.
74. Van Cauter E, Spiegel K, Tasali E, Leproult R. Metabolic consequences of sleep and sleep loss. Sleep Med 2008; 9(Suppl 1): S23- 28.
75. Silverberg DS, Oksenberg A. Are sleep-related breathing disorders important contribuiting factors to the production of essential hypertension?. Curr Hypertens Rep 2001; 3: 209-15.
76. Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001; 19: 2271-7.
77. Lavie P, Herard P, Hofftein V. Obstructive sleep apnea syndrome as a risk factor for hypertension: population study. BMJ 2000; 320: 479-82.
78. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep disordered breathing and hypertension. New Engl J Med 2000; 342: 1378-84.
79. O'Connor GT, Caffo N, Newman AB, et al. prospective study of the association between sleep-disordered breathing and hypertension: The Sleep Heart Health Study. Am J Respir Crit Care Med 2009; 179: 1159-64.
80. Mancia G, Fagard R, Narkiewicz K, et al. ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1925-38.
81. Bixler EO, Vgontzas AN, Lin HM, et al. Association of hypertension and sleep-disordered breathing. Arch Intern Med 2000; 160: 2289-95.
82. Haas DC, Foster GL, Nieto J, et al. Age-dependent associations between sleep-disordered breathing and hypertension. Circulation 2005; 111: 614-21.
83. Cano-Pumarega I, Durán-Cantolla J, Aizpuru F, et al. Obstructive sleep apnea and systemic hypertension. Longitudinal study in the general population: the Vitoria Sleep Cohort. Am J Respir Crit Care Med 2011; 184: 1299-304.
84. Masa JF, Corral J, Sanchez de Cos J, et al. Effectiveness of three sleep apnea management alternatives. Sleep 2013; 36: 1799-807.
85. Verdecchia P, Schillaci G, Guerrieri M, et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81: 528-36.
86. Verdecchia P, Porcellati C, Schillaci G, et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension 1994; 24: 793-801. [Erratum in: Hypertension 1995; 25: 462.
87. Pankow W, Nabe B, Lies A, et al. Influence of sleep apnea on 24- hour blood pressure. Chest 1997; 112: 1253-8.
88. Pucci G, Fiorenzano G, Schillaci G. Obstructive sleep apnea and reverse dipping: the bad companions. J Hypertens 2014; 32: 1964- 66.
89. Davies RJ, Crosby J, Vardi-Visy K, Clarke M, Stradling JR. Noninvasive beat to beat arterial blood pressure during non-REM sleep in obstructive sleep apnoea and snoring. Thorax 1994; 49: 335-9.
90. Steinhorst AP, Gonçalves SC, Oliveira AT, et al. Influence of sleep apnea severity on blood pressure variability of patients with hypertension. Sleep Breath 2014; 18: 397-401.
91. Loredo JS, Ancoli-Israel S, Dimsdale JE. Sleep quality and blood pressure dipping in obstructive sleep apnea. Am J Hypertens 2001; 14: 887-92.
92. Hla KM, Young T, Finn L, Peppard PE, Szklo M, Stubbs M. Longitudinal association of sleep-disordered breathing and nondipping nocturnal blood pressure in the Wisconsin Sleep Cohort Study. Sleep 2008; 31: 795-800.
93. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of Council for high Blood Pressure Research. Circulation 2008; 117: e510-e526.
94. Gonçalves SC, Martinez D, Gus M, et al. Obstructive sleep apnea and resistant hypertension: a case control study. Chest 2007; 132: 1858-62.
95. Pedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension 2011; 58: 811-7.
96. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 2007; 131: 453-9.
97. Friedman O, Bradley TD, Chan CT, Parkes R, Logan AG. Relationship between overnight rostral fluid shift and obstructive sleep apnea in drug-resistant hypertension. Hypertension 2010; 56: 1077- 82.
98. Montesi SB, Edwards BA, Malhotra A, Bakker JP. The effect of continuous positive airway pressure treatment on blood pressure: a systematic review and meta-analysis of randomized controlled trials. J Clin Sleep Med 2012; 8: 587-96.
99. Durán-Cantolla J, Aizpuru F, Montserrat JM, et al. Continuous positive airway pressure as treatment for systemic hypertension in people with obstructive sleep apnoea: randomised controlled trial. BMJ 2010; 341: 5991.
100. Barbé F, Durán-Cantolla J, Capote F, et al. Long-term effect of continuous positive airway pressure in hypertensive patients with sleep apnea. Am J Respir Crit Care Med 2010; 181: 718-26.
101. Lozano L, Tovar JL, Sampol G, et al. Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized controlled trial. J Hypertens 2010; 28: 2161-8.
102. Litvin AY, Sukmarova ZN, Elfimova EM, et al. Effects of CPAP on "vascular" risk factors in patients with obstructive sleep apnea and arterial hypertension. Vasc Health Risk Manag 2013; 9: 229- 35.
103. Pedrosa RP, Draguer LF, de Paula LK, Amaro AC, Bortolotto LA, Lorenzi-Filho G. Effects of obstructive sleep apnea treatment on blood pressure in patients with resistant hypertension: a randomized trial. Chest 2013; 144: 1487-94.
104. Martínez-García MA, Capote F, Campos-Rodriguez F, et al. Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension. The HIPARCO randomized clinical trial. JAMA 2013; 310: 2407-15.
105. Lloberes P, Sampol G, Espinel E, et al. A randomized controlled study of CPAP effect on plasma aldosterone concentration in patients with resistant hypertension and obstructive sleep apnea. J Hypertens 2014; 32: 1650-7.
106. Muxfeldt ES, Margallo V, Costa LM, et al. Effects of continuous positive airway pressure treatment on clinic and ambulatory blood pressures in patients with obstructive sleep apnea and resistant hypertension: a randomized controlled trial. Hypertension 2015; 65: 736-42.
107. Iftikhar IH, Valentine CW, Bittencourt LR, et al. Effects of continuous positive airway pressure on blood pressure in patients with resistant hypertension and obstructive sleep apnea: a meta-analysis. J Hypertens 2014; 32: 2341-50.
108. Konecny T, Kuniyoshi FAS, Orban M, et al. Under-diagnosis of sleep apnea in patients after acute myocardial infarction. J Am Coll Cardiol 2010; 56: 742-3.
109. Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the Sleep Heart Health Study. Circulation 2010; 122: 352-60.
110. Shah NA, Yaggi HK, Concato J, Mohsenin V. Obstructive sleep apnea as a risk factor for coronary events or cardiovascular death. Sleep Breath 2010; 14: 131-6.
111. Gami AS, Howard DE, Olson EJ, Somers VK. Day-night pattern of sudden death in obstructive sleep apnea. N Engl J Med 2005; 352: 1206-14.
112. Campos-Rodriguez F, Peña-Griñan N, Reyes-Nuñez N, et al. Mortality in obstructive sleep apnea-hypopnea patients treated with positive airway pressure. Chest 2005; 128: 624-33.
113. Barbé F, Durán-Cantolla J, Sánchez-de-la-Torre M, et al. Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial. JAMA 2012; 307: 2161-8.
114. Johnson KG, Johnson DC. Frequency of sleep apnea in stroke and TIA patients: a meta-analysis. J Clin Sleep Med 2010; 6: 131-7.
115. Redline S, Yenokyan G, Gottlieb DJ, et al. Obstructive sleep apneahypopnea and incident stroke: the Sleep Heart Health Study. Am J Respir Crit Care Med 2010; 182: 269-77.
116. Li M, Hou WS, Zhang XW, Tang ZY. Obstructive sleep apnea and risk of stroke: a meta-analysis of prospective studies. Int J Cardiol 2014; 172: 466-9.
117. Martínez-García MA, Soler-Cataluña JJ, Ejarque-Martínez L, et al. Continuous positive airway pressure treatment reduces mortality in patients with ischemic stroke and obstructive sleep apnea: a 5-year follow-up study. Am J Respir Crit Care Med 2009; 180: 36-41.
118. Martínez-García MA, Campos-Rodriguez F, Soler-Cataluña JJ, Catalan-Serra P, Roman-Sanchez P, Montserrat JM. Increased incidence of nonfatal cardiovascular events in stroke patients with sleep apnoea: eff ect of CPAP treatment. Eur Respir J 2012; 39: 906-12.
119. Hsu C-Y, Vennelle M, Li H-Y, Engleman HM, Dennis MS, Douglas NJ. Sleep-disordered breathing after stroke: a randomised controlled trial of continuous positive airway pressure. J Neurol Neurosurg Psychiatry 2006; 77: 1143-9.
120. Ryan CM, Bayley M, Green R, Murray BJ, Bradley TD. Influence of continuous positive airway pressure on outcomes of rehabilitation in stroke patients with obstructive sleep apnea. Stroke 2011; 42: 1062-7.
121. Parra O, Sánchez Armengol A, Bonnin M, et al. Early treatment of obstructive apnoea and stroke outcome: a randomised controlled trial. Eur Respir J 2011; 37: 1128-36.
122. Kasai T, Floras JS, Bradley TD. Sleep apnea and cardiovascular disease: a bidirectional relationship. Circulation 2012; 126: 1495- 510.
123. Shahar E, Whitney CW, Redline S, et al. Sleep-disordered breathing and cardiovascular disease: Cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001; 163: 19-25.
124. Yumino D, Wang H, Floras JS, et al. Relationship between sleep apnoea and mortality in patients with ischaemic heart failure. Heart 2009; 95: 819-24.
125. Wang H, Parker JD, Newton GE, et al. Influence of obstructive sleep apnea on mortality in patients with heart failure. J Am Coll Cardiol 2007; 49: 1625-31.
126. Tkacova R, Rankin F, Fitzgerald FS, et al. Effects of continuous positive airway pressure on obstructive sleep apnea and left ventricular afterload in patients with heart failure. Circulation 1998; 98: 2269-75.
127. Mansfield DR, Gollogly NC, Kaye DM, et al. Controlled trial of continuous positive airway pressure in obstructive sleep apnea and heart failure. Am J Respir Crit Care Med 2004; 169: 361-6.
128. Kaneko Y, Floras JS, Usui K, et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med 2003; 348: 1233-41.
129. Kaye DM, Mansfield D, Aggarwal A, et al. Acute effects of continuous positive airway pressure on cardiac sympathetic tone in congestive heart failure. Circulation 2001; 103: 2336-8.
130. Usui K, Bradley TD, Spaak J, et al. Inhibition of awake sympathetic nerve activity of heart failure patients with obstructive sleep apnea by nocturnal continuous positive airway pressure. J Am Coll Cardiol 2005; 45: 2008-11.
131. Wang H, Parker JD, Newton GE, et al. Influence of obstructive sleep apnea on mortality in patients with heart failure. J Am Coll Cardiol 2007; 49: 1625-31.